Luc Van Rompaey

Luc is an experienced drug hunter and entrepreneur. He obtained a PhD in protein engineering and moved on to oncology postdoc positions at VIB-KU Leuven & St Jude Children’s Research Hospital. He joined Galapagos in 2000, led a target discovery unit and started an international drug discovery department. He managed rheumatoid arthritis, osteoarthritis, osteoporosis and oncology collaborations with GSK, Eli Lilly, Servier, JnJ. He is a co-inventor of Filgotinib and contributed to its early clinical development and outlicensing to abbvie. He joined argenx in 2014 as VP Translational Medicine, guided late stage research and translational clinical development, resulting in Cusatuzumab’s outlicensing to JnJ. He is the author of over 40 publications, reviews and patents. Building on his R&D and managerial expertise and network, Luc conceptualized dualyx NV in 2019 and raised a significant seed financing round with an international consortium of high quality venture capital firms.